Veracyte, a US-based molecular diagnostics company in the field of molecular cytology, has completed the final tranche of its $28m series C financing which includes GE Ventures (the corporate venturing unit of industrial conglomerate General Electric) as a new investor. All previous investors participated in the round, including venture capital and private equity investors Domain Associates, Kleiner Perkins Caufield & Byers, TPG Biotech, and Versant Ventures.
Bonnie Anderson, Veracyte’s co-founder and chief executive officer., said: “We are pleased to have the support of GE Ventures, as well as of our current investors. This funding will help Veracyte expand availability of our Afirma Thyroid FNA Analysis to help more patients with inconclusive thyroid nodule fine needle aspiration (FNA) biopsy results potentially avoid unnecessary thyroid surgery. This additional capital will also support our investment in research and development of new products similarly designed to help patients avoid unnecessary invasive procedures, while reducing healthcare costs.”
Veracyte was founded in 2008. It completed a $28m series B round financing in June 2010.